![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
B Monsarrat, E Mariel, S Cros, M Gares, D Guenard, F Gueritte-Voegelein and M Wright
Centre National de la Recherche Scientifique, Laboratoire de Pharmacologie et Toxicologie Fondamentales, Toulouse, France.
The elimination of nonradioactive taxol in bile and urine was investigated in the rat after administration via the caudal vein (10 mg/kg). As in humans, no metabolites of taxol were detected by HPLC in rat urine, and only 10% of the injected taxol was recovered in urine over a 24-hr period. In contrast, 11.5% and 29% of the injected taxol was recovered in rat bile as unchanged taxol and metabolites, respectively. Among the nine taxol metabolites detected by HPLC, the side chain at C13, which is required for pharmacological activity, had been removed in only one minor metabolite, baccatin III. The chemical structures of the two major hydroxylated metabolites were determined by mass spectrometry (fast atom bombardment and desorption chemical ionization) and 1H-NMR spectroscopy. One was a taxol derivative hydroxylated on the phenyl group at C3' of the side chain at C13, while the other corresponded to a taxol derivative hydroxylated in the m- position on the benzoate of the side chain at C2. Although these two major taxol metabolites were as active as taxol in preventing cold microtubule disassembly, they were, respectively, 9 and 39 times less cytotoxic as taxol on in vitro L1210 leukemia growth. These results show for the first time that there is a significant hepatic metabolism of taxol.
This article has been cited by other articles:
|
|
 |
|
  R. Vaclavikova, P. Soucek, L. Svobodova, P. Anzenbacher, P. Simek, F. P. Guengerich, and I. Gut DIFFERENT IN VITRO METABOLISM OF PACLITAXEL AND DOCETAXEL IN HUMANS, RATS, PIGS, AND MINIPIGS Drug Metab. Dispos., June 1, 2004; 32(6): 666 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Czejka, J. Schueller, H. Schnait, B. Springer, and I. Eder Clinical pharmacokinetics and metabolism of paclitaxel after a three-hour infusion: comparison of two preparations Journal of Oncology Pharmacy Practice, December 1, 2003; 9(4): 129 - 139. [Abstract] [PDF]
|
|
|
|
|
|
T. Cresteil, B. Monsarrat, J. Dubois, M. Sonnier, P. Alvinerie, and F. Gueritte Regioselective Metabolism of Taxoids by Human CYP3A4 and 2C8: Structure-Activity Relationship Drug Metab. Dispos., April 1, 2002; 30(4): 438 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Kang, W. D. Figg, Y. Ando, M. V. Blagosklonny, D. Liewehr, T. Fojo, and S. E. Bates The P-Glycoprotein Antagonist PSC 833 Increases the Plasma Concentrations of 6{{alpha}}-Hydroxypaclitaxel, a Major Metabolite of Paclitaxel Clin. Cancer Res., June 1, 2001; 7(6): 1610 - 1617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Monsarrat, E. Chatelut, I. Royer, P. Alvinerie, J. Dubois, A. Dezeuse, H. Roché, S. Cros, M. Wright, and P. Canal Modification of Paclitaxel Metabolism in a Cancer Patient by Induction of Cytochrome P450 3A4 Drug Metab. Dispos., March 1, 1998; 26(3): 229 - 233. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. L. Betcher and N. Burnham Taxol Journal of Pediatric Oncology Nursing, January 1, 1993; 10(1): 37 - 39. [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
